Objectives-Orthotopic heart transplantation is the standard of care for end-stage heart disease. Left ventricular assist device implantation offers an alternative treatment approach. Left ventricular assist device practice has changed dramatically since the 2008 Food and Drug Administration approval of the HeartMate II (Thoratec, Pleasanton, Calif), but at what societal cost? The present study examined the cost and efficacy of both treatments over time.
United States each year. 1, 2 More federal funds are spent on congestive heart failure in the United States than any other diagnosis, and a disproportionate amount of these funds is spent on the treatment of advanced heart failure. 3 In patients with advanced disease, the options are limited, and orthotopic heart transplantation (OHT) is widely accepted as the therapy of choice, with 1-year post-transplant survival rates of roughly 85%. 4 Western societies have supported heart transplantation as an acceptable use of healthcare resources; however, the demand for this life-saving treatment far outstrips the availability of suitable donor organs. The OHT numbers in the United States have remained stable during the past decade at approximately 2000 patients treated annually, a mere fraction of the population who could benefit from this treatment. 4 In 1964, the National Institutes of Health artificial heart program was created with the stated goal of putting a man-made heart into a human by the end of the decade. Despite the large investment of both public and private funds, little palpable progress was made until 2001 when the landmark Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial demonstrated a stark improvement in survival when patients with advanced heart failure underwent HeartMate XVE (Thoratec, Pleasanton, Calif) left ventricular assist device (LVAD) implantation compared with those supported with conventional medical therapy. 5 In response to that trial, the Centers for Medicare and Medicaid Services authorized reimbursement for the use of Food and Drug Administration-approved LVADs as long-term destination therapy in October 2003. 6, 7 More recently, a second leap forward occurred with the replacement of first-generation pulsatile LVADs with newer continuous-flow devices such as the HeartMate II LVAD (Thoratec), which was approved by the Food and Drug Administration for bridge-to-transplantation in April 2008 and for destination therapy in January 2010. 8, 9 Since the April 2008 approval, the HeartMate II has rapidly taken over market share as the most widely used implantable LVAD in the United States. 10 Additionally, patient outcomes have rapidly improved with this newer device, with 1-year survival rates now approximately 80%, a percentage almost equivalent to the reference standard of heart transplantation. 10 Although it took 4 decades longer than expected, the fruits of the 1964 investment have now been realized in the form of the HeartMate II, a man-made artificial blood pump that can be successfully implanted into a human, with resulting survival rates almost equivalent to transplantation. Despite this fantastic feat of modern medicine, the cost of this achievement and feasibility of widespread use must be carefully weighed. The purpose of the present study was to examine both OHT and LVAD usage and cost patterns in the years surrounding the initial HeartMate II bridge-to-transplant approval in April 2008-to shed light on current trends and possibly to help guide future use.
METHODS

Data Sources
Data were abstracted from the 2005 through 2009 Nationwide Inpatient Sample (NIS). The NIS is the largest Healthcare Cost and Utilization Project all-payer inpatient database, sponsored by the Agency for Healthcare Research and Quality. The NIS contains data from more than 8 million hospital discharges annually from 1050 hospitals located in 44 states, representing 95% of all US nonfederal hospital discharges. 11 The Agency for Healthcare Research and Quality has developed appropriately scaled discharge weights to generate national estimates of hospitalizations from the NIS. 12 These weights help compare hospitalization rates across years despite the varying number of states participating each year. The Health-care Cost and Utilization Project validates the NIS for biases by comparing it with other population-based data sets. 13 In the present analysis, when more than 2% of the variables for a particular record had data missing at random, we excluded the record from the computations. No imputations were performed, and the data sets were reviewed for any systematically missing values and accordingly excluded from evaluation. Data reporting met the NIS data use agreement as established by the Healthcare Cost and Utilization Project. The NIS databases contain de-identified administrative level data and were not considered human subjects research and, hence, were exempted from review by the University of Virginia's human investigation committee.
Patient Selection
Patients were identified based on whether they had been recipients of an OHT or an implantable LVAD. The patients were selected using the "International Statistical Classification of Diseases and Related Health Problems, 9th Revision, Clinical Modification" codes. All 15 procedure codes (PR1-PR15) were queried to identify patients having undergone operative procedures using the following "International Statistical Classification of Diseases and Related Health Problems, 9th Revision, Clinical Modification" codes: OHT, 37.5 (heart replacement procedures), 37.51 (heart transplantation), 33.6 (combined heart-lung transplantation); and LVAD, 37.66 (insertion of implantable heart assist system). Only patients older than 18 years of age were selected. Those with multiple procedural codes were assigned to the groups according to the first procedure code to avoid the possibility of double counting any patient record. The records were selected only once per any given group (according to the surgical procedure) and examined with the intent to perform a comprehensive analysis of the null hypothesis. Patient risk factors were assessed using 30 different Agency for Healthcare Research and Quality comorbidities.
Total Charges and Cost-to-Charge
The total charges for each analyzed record were obtained from the Healthcare Cost and Utilization Project. Computations to calculate costs were completed by multiplying the total charges from the discharge record by the all-payer inpatient cost-to-charge ratio. These costto-charge ratios were calculated using annual reports by hospitals to the Centers for Medicare and Medicaid Services. The hospital-specific cost-to-charge was computed when available, and the weighted group average was used for calculations when the hospitalspecific cost-to-charge was not available (approximately 11% of the time).
Outcomes of Interest
Treatment usage, in-hospital mortality, cost, and discharge disposition after OHT and LVAD were our primary outcomes of interest. Complications were identified and limited to the hospital admission-recorded "International Statistical Classification of Diseases and Related Health Problems, 9th Revision, Clinical Modification" codes. Because the NIS contains inpatient data only, complications occurring after hospital discharge could not be evaluated.
Statistical Analysis
The strength of the association between variables was examined using the appropriate hypothesis test. The significance of the differences between the unadjusted proportions for categorical variables was evaluated using the Pearson chi-square test. Differences between the mean values of unadjusted continuous variables were assessed using single-factor analysis of variance models. Unadjusted in-hospital mortality across the groups was calculated. All data were analyzed using IBM SPSS Complex Samples, version 20 (SPSS, IBM, Armonk, NY).
RESULTS
Treatment Usage and Patient Characteristics
From January 2005 to December 2009, 15,783 patients underwent either OHT or implantation of an LVAD. The trends in treatment usage have shown that OHT increased marginally during the examined period and was consistent with the widely reported ~2000 heart transplants performed annually in the United States ( Figure 1 ). 4 However, the LVAD implantation rates nearly tripled, surpassing OHT for the first time in 2009 (P <.001). The increase in LVAD implantation rates started in 2008, the same year the Food and Drug Administration approved the continuous-flow HeartMate II LVAD. Examining the characteristics of these patients over time, several interesting observations could be made. First, both treatments were largely performed on men with an average age of about 50 years ( Table 1) . Most of these patients were white, but all racial groups were roughly represented in approximate proportion to their relative contributions to the US population. Across the board, black patients were slightly overrepresented, given that they constituted 13%of the US population as of the 2010 census (vs 16%of OHT and 18% of LVAD), and Hispanic patients were slightly underrepresented, because they constitute 16% of the US population (vs 11% of OHT and 8% of LVAD). 14 All 4 income quartiles, as determined by zip code, were well represented for both LVAD and OHT, suggesting these life-saving procedures are being offered equally to eligible patients, regardless of income. As expected, patients had a variety of comorbidities, with the most common being hypertension, fluid and electrolyte abnormalities, diabetes, coagulopathy, and renal failure. Most admissions for heart transplantation were routine; however, this percentage declined over time. LVAD recipients were more likely to have been transferred from another hospital or admitted through the hospital emergency department.
Mortality
All mortality estimates examined mortality before hospital discharge only. As expected, mortality for OHT was low, ranging from 3.8%to 6.5%. Mortality for LVAD implantation was high but decreased dramatically during the examined period, from 42.3% in 2005 to 17.0% in 2009 (P <.001; Figure 2 ). Major improvements in the LVAD mortality rates started in 2008, the same year Food and Drug Administration approval of the HeartMate II LVAD occurred. Therefore, despite any learning curve issues that often accompany the initial use of a new device, mortality continued to decline. 
Disposition
Those patients discharged alive were classified according to routine discharge to home, discharge home with home health services, discharge to a skilled nursing facility or intermediate care facility, or discharge to a rehabilitation unit or short-term hospital. The OHT survivors had routine discharge to home more frequently, and the LVAD recipients were more likely to be discharged to a skilled nursing facility or intermediate care facility or to receive home health services after discharge (Figure 4) . This was perhaps not surprising, because the LVAD recipients might require increased assistance with care of the driveline exit site wound and need assistance familiarizing themselves and their families with the additional aspects of the device, including proper care of the power-based unit, control unit, batteries, and battery pack. The usage of home health services increased for both OHT and LVAD recipients throughout the study period.
DISCUSSION
The present study has shed light on evolving trends in the surgical treatment of advanced heart failure on a national level and provides reason for both great optimism and grave concern. In the 5 short years from 2005 to 2009, the LVAD implantation rates nearly tripled and in-hospital mortality decreased by more than one half. This rapid and significant decrease in procedure-related mortality on a national level is likely unprecedented and speaks to the momentous improvements being made in the field of mechanical circulatory assistance. Despite this, during the same short period, per patient, the LVAD hospitalization cost increased by 17% and the nationwide estimated LVAD hospitalization expenditures more than tripled. On the one hand, the dramatic improvement witnessed in LVAD mortality during the short study period suggests the future of LVAD therapy is bright and limitless. On the other hand, the accelerating increase in the nationwide cost of this treatment cast doubts on the future financial viability of this invaluable therapy. In presenting these data, we do not intend to argue either the former or the latter point of view. That argument rests on the question of what a life, a year, or a month is worth and was outside the scope of this project. We wish solely to point out the facts, provide information for discussion, and urge consideration of these questions as our specialty embarks on an era in which the promises of the 1964 National Institutes of Health artificial heart program are finally now a reality.
History often has a way of repeating itself, albeit with slight variations. In 1980, when considering a decision of whether Medicare would begin reimbursement for heart transplantation procedures, the Secretary of the Department of Health and Human Services, Patricia Roberts Harris, commissioned a major study to examine "all aspects of heart transplants, including the scientific, social, economic, and ethical issues, and, in particular, the impact of a possible Medicare decision to pay for heart transplants on the Medicare program, Medicare beneficiaries, and providers of health care." 15, 16 The Secretary further argued that Department of Health and Human Services would require future new technologies to demonstrate their beneficial "social consequences" before "financing their wide distribution." 17 Fortunately, a decision was made to cover heart transplantation despite its high cost and, at the time, variable outcomes. Heart transplantation has since saved tens of thousands of lives and remains the reference standard against which all other therapies for advanced heart failure are judged. The field of mechanical circulatory assist now finds itself at a similar crossroads. Clearly, LVADs can no longer be considered merely an experimental therapy; however, their place in the larger picture of societal care of the patients with heart failure is still somewhat undefined, especially when it comes to destination therapy.
To shed insight on these considerations, multiple previous studies have addressed the issue of LVAD cost, and several have looked beyond the cost at efforts to define quality. A cost analysis of a subset of patients in the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure trial showed that cost of the implant-related hospitalization averaged $210,187. 18 Three years later, a single-institution analysis demonstrated a reduction of 40%, with implant hospitalization cost averaging $128,084, suggesting that with experience, care could be streamlined and the cost reduced. 6 A more recent study analyzed the costs of a subset of patients in the HeartMate II destination therapy trial 19 and found that inflation-adjusted hospital cost averaged $193,812, very similar to our nationwide estimates. 20 In an effort to address quality, Rogers and colleagues 21 recently compared the LVAD costs and outcomes with those for optimal medical management and demonstrated that although the LVAD costs were much greater for a 5-year period ($360,407 vs $62,856), the quality-adjusted life years were also greater with LVAD (1.87 vs 0.37). Using these data, the incremental cost-effectiveness ratio of a continuous-flow LVAD was calculated to be $198,184 per quality-adjusted life year. Typically, $50,000 per qualityadjusted life year is used as the benchmark to determine adequate cost-effectiveness of a given treatment. Therefore, despite the rapid improvements being made in LVAD therapy, significant progress is still needed to meet accepted cost-effectiveness benchmarks.
Although the cited studies provide useful information for a conversation on the relative merits of LVAD therapy, no previous studies have used a national database to compare LVAD cost to the standard of OHT. We believe the present study adds to the discussion by effectively providing a "bird's eye" view of the changes occurring in the surgical treatment of advanced heart failure. To determine the "social consequences" of LVAD therapy before "financing their wide distribution," this larger perspective must be captured. As healthcare distribution in the United States changes and evolves, the pressures of cost containment and comparative effectiveness will inevitably affect the availability of various treatment approaches and surgical options for patients with advanced heart failure. To remain a part of that conversation and to help influence the coming changes, our field must take a proactive approach, keeping the best interests of both our patients and our larger community in mind. With the field of mechanical circulatory assist at a crossroads, care must be taken with regard to the dissemination of this new technology. Perhaps a concerted effort toward approaching established cost-effectiveness benchmarks, although improved efficiency and streamlined care, should precede the widespread use of LVAD therapy to nonheart transplant centers around the United States. Progress does not come easily in any field and especially with the future envisioned in 1964 finally now in clear view, it would be difficult to turn back. We intend to pursue the future of ventricular assist and heart transplantation but always hope to maintain a realistic awareness of the greater surroundings within which we operate.
Study Limitations
A number of potential limitations of the present study are worth noting. First, the NIS is an administrative discharge database, and patients cannot be tracked after leaving the hospital. Therefore, all cost and mortality rates reported referred to the index admission only, and we were unable to extrapolate the cost or mortality related to subsequent admissions during the same year or in succeeding years. Similarly, we could not determine which or how many LVAD recipients underwent subsequent heart transplantation. For these 2 reasons, our cost approximations have surely underestimated the true per-patient cost of these therapies. Furthermore, the NIS derives data from a 20% yearly sample of US hospitals with the sample designed to approximate the national distribution of certain hospital characteristics, including volume, academic status, location, and size. Although the NIS sampling procedure is statistically sound and has been used extensively to research national trends in healthcare delivery, elements of our presented data could reflect year-to-year sampling variations. Additionally, granularity is limited, and we could not examine individual patient characteristics. Similarly, no quality of life data were available, and we had no mechanism to compare the relative quality of life after LVAD or OHT nor could we address the qualityadjusted life years or any similar computations. Despite these potential limitations, the NIS data set allows for analysis of a large sample size with a wide geographic distribution, providing an excellent data source for examination of healthcare trends over time.
CONCLUSIONS
LVADs offer a promising alternative to OHT for those patients with advanced heart failure who are either ineligible for transplantation or for whom an acceptable donor organ is not yet available. . In January 2010, the HeartMate II LVAD was approved for destination therapy, and newer continuous-flow devices still in development will soon follow suit. As the technology and experience progress, LVAD outcomes will continue to improve and are rapidly approaching the reference standard of heart transplantation. In the coming years, a society that has long footed the bill for heart transplantation will have to determine when, and whether, additional progress is worth the price. 
